Market News
Global Microneedle Flu Vaccine Market: Key Developments
- On December 14, 2022, Vaxess Technologies, Inc., a life sciences company developing a shelf-stable vaccine patch with potential for self-application, announced positive interim results from a first-in-man trial of VX-103, a monovalent seasonal influenza vaccine patch
- On June 17, 2020, MICRODERMICS INC, a medical device company commercializing a novel microneedle delivery and biosensing platform, announced strategic merger & acquisition or technology out-licensing opportunities with pharma, cosmetic, and biotech companies for its microneedle platforms
- On August 6, 2020, EVERSANA, the leading provider of global commercial services to the life sciences industry, announced the acquisition of Zosano Pharma Corporation, a clinical-stage biopharmaceutical company, to commercialize and distribute Qtrypta, a transdermal microneedle product
- On November 18, 2020, Sanofi, a multinational pharmaceutical and healthcare company announced that the European Commission has granted marketing authorization for Supemtek, a quadrivalent (four-strain) recombinant influenza vaccine, for the prevention of influenza in adults aged 18 years and older
- The increasing clinical trials, merger and acquisitions, product approvals, etc. is expected to generate new opportunities for the global microneedle flu vaccine market.